Literature DB >> 22922994

Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy.

Sare Sipal1, Zekai Halici, Ilhami Kiki, Beyzagul Polat, Abdulmecit Albayrak, Fatih Albayrak, Emre Karakus, Selina Aksak, Berna Ozturk, Cemal Gundogdu.   

Abstract

The presence of liver disease in patients with progressively worsening insulin resistance may not be recognized until patients develop manifestations of the metabolic syndrome such as diabetes, hypertension, hyperlipidemia, and vascular disease. It was aimed to investigate whether three angiotensin II type 1 receptor antagonists (ARBs) (olmesartan, losartan, and valsartan) had preventive effect against hepatic fibrosis and this was a common characteristic among ARBs. In current study, 25 adult male rats were used and divided into five groups: the non-diabetic healthy group, alloxan induced diabetic (AID) control group, AID losartan group, AID valsartan group and AID olmesartan group. According to numerical density of hepatocytes, significant difference was found between the non-diabetic healthy group and diabetic control group. All treatments groups were significant when compared to diabetic control group. In diabetic control group it was examined swelling, irregular cristae arrangement in some of mitochondria. It was also determined mitochondria membrane degeneration in some areas of section profiles. In diabetic rats treated with losartan group, there were necrotic hepatocytes. In diabetic rats treated with valsartan group, predominantly, findings were similar to losartan group. In diabetic rats treated with olmesertan group, plates of hepatocytes were quite regular. There were hardly necrotic cells. Not only other organelles such as RER, SER and lysosom but also mitochondrial structures had normal appearance. In the diabetic control group electron microscopy revealed edema in both the cytoplasm and perinuclear area and the nuclear membranes appeared damaged. In conclusion, it was established that the most protective ARB the liver in diabetic rats was olmesartan, followed by losartan.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922994     DOI: 10.1007/s10735-012-9441-z

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  44 in total

1.  Antidiabetic and hypolipidemic effects of Momordica cymbalaria Hook. fruit powder in alloxan-diabetic rats.

Authors:  B K Rao; M M Kesavulu; R Giri; C Appa Rao
Journal:  J Ethnopharmacol       Date:  1999-10       Impact factor: 4.360

2.  The efficiency of systematic sampling in stereology--reconsidered.

Authors:  H J Gundersen; E B Jensen; K Kiêu
Journal:  J Microsc       Date:  1999-03       Impact factor: 1.758

3.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Ding-Guo Li; Han-Ming Lu; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Jing Zhang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

4.  Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.

Authors:  Wei Xu; Shiling Song; Yanqing Huang; Zuojiong Gong
Journal:  J Gastroenterol Hepatol       Date:  2006-08       Impact factor: 4.029

Review 5.  The role of vasoactive mediators in portal hypertension.

Authors:  J C García-Pagán; J Bosch; J Rodés
Journal:  Semin Gastrointest Dis       Date:  1995-07

6.  Effects of diabetes mellitus on the rat liver during the postmenopausal period.

Authors:  Deniz Unal; Selina Aksak; Zekai Halici; Ozlem Sengul; Beyzagul Polat; Bunyami Unal; Mesut Halici
Journal:  J Mol Histol       Date:  2011-05-21       Impact factor: 2.611

7.  Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

Authors:  David V Erbe; Katherine Gartrell; Yan-Ling Zhang; Vipin Suri; Steven J Kirincich; Sarah Will; Mylene Perreault; Suyue Wang; James F Tobin
Journal:  Vascul Pharmacol       Date:  2006-05-16       Impact factor: 5.773

8.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

9.  Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells.

Authors:  G Svegliati-Baroni; S Saccomanno; H van Goor; P Jansen; A Benedetti; H Moshage
Journal:  Liver       Date:  2001-02

Review 10.  The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.

Authors:  Ulrike Muscha Steckelings; Franziska Rompe; Elena Kaschina; Thomas Unger
Journal:  Fundam Clin Pharmacol       Date:  2009-10-09       Impact factor: 2.748

View more
  5 in total

1.  The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus.

Authors:  A Cayir; R A Ugan; A Albayrak; D Kose; E Akpinar; Y Cayir; H T Atmaca; Z Bayraktutan; M Kara
Journal:  J Endocrinol Invest       Date:  2015-04-07       Impact factor: 4.256

2.  Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice.

Authors:  Wenjun Ji; Xinlin Chen; Juan Lv; Meng Wang; Shuting Ren; Bingxiang Yuan; Bing Wang; Lina Chen
Journal:  Int J Endocrinol       Date:  2014-08-11       Impact factor: 3.257

3.  Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin.

Authors:  Pieter Spincemaille; Gursimran Chandhok; Andree Zibert; Hartmut Schmidt; Jef Verbeek; Patrick Chaltin; Bruno P Cammue; David Cassiman; Karin Thevissen
Journal:  Microb Cell       Date:  2014-10-24

Review 4.  Thrombospondin-1: A Key Protein That Induces Fibrosis in Diabetic Complications.

Authors:  Linhao Xu; Yong Zhang; Jian Chen; Yizhou Xu
Journal:  J Diabetes Res       Date:  2020-06-11       Impact factor: 4.011

5.  Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Authors:  Daisuke Yoshihara; Masanori Kugita; Mai Sasaki; Shigeo Horie; Koichi Nakanishi; Takaaki Abe; Harold M Aukema; Tamio Yamaguchi; Shizuko Nagao
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.